Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TVB-3567 · 1 trial · 1 indication
Area under the concentration-time curve from time zero until the last observed concentration
Area under the concentration-time curve from time zero to infinity
Maximum concentration measurement in plasma
| Arm | Type | Description |
|---|---|---|
| Part A (SAD in Healthy Participants) | EXPERIMENTAL | - |
| Part B (Food Effect) | EXPERIMENTAL | - |
| Part C (MAD in Healthy Participants) | EXPERIMENTAL | - |
| Part D (MAD in Acne Participants) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TVB-3567 | DRUG | Orally administered capsule |
| Placebo | DRUG | Orally administered capsule |
Inclusion Criteria: Healthy Participants (Parts A, B and C) 1. Healthy, adult, male or female 18-55 years of age 2. Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 3. Medically healthy with no clinically significant medical history 4. Understands the study procedures in the informed consent form (ICF)...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 1 | PHASE3 | Undisclosed |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 1% Clascoterone |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE1 | Acne mRNA vaccine |
| Hoth Therapeutics, Inc. | HOTH | 1 | PHASE2 | HT-001 2%, HT-001 1%, HT-001 0.5% |
| Sagimet Biosciences Inc. Class A | SGMT | 1 | PHASE1 | TVB-3567 |
| Bausch Health Companies Inc. | BHC | 1 | - | clindamycin , adapalene and benzoyl peroxide |
TVB-3567 is an investigational small molecule being developed for the treatment of acne. It is currently in Phase 1 clinical development, with a study evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants with or without acne.
TVB-3567 targets FASN, a protein involved in fatty acid synthesis. By inhibiting FASN, the drug may reduce sebum production, which is a key factor in the development of acne. This mechanism is being investigated in early-stage clinical trials.
TVB-3567 is being developed by Sagimet Biosciences Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial of TVB-3567 for acne, with the study currently recruiting participants.
TVB-3567 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is evaluating the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants with or without acne.
TVB-3567 is being studied in a Phase 1 clinical trial with the identifier NCT06989840. This randomized, double-blind, controlled study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of TVB-3567 in healthy participants with or without acne. The trial is recruiting 128 participants in the United States and Australia.
TVB-3567 is a unique investigational compound developed by Sagimet Biosciences. No alternative names for TVB-3567 have been reported. It is a small molecule targeting FASN, and it is being studied specifically for the treatment of acne.